Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
Sept. 26, 2019: Racial disparities in the PrEP continuum; HIV and ocular syphilis; Kaposi sarcoma among people with well-suppressed HIV; modifiable risk factors in the management of chronic kidney disease.
Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
The first case of Fanconi syndrome associated with PrEP was reported in a poster at the 18th International Workshop on Comorbidities and Adverse Drug Reactions in HIV.
Three studies offer reassuring news that adverse kidney changes that accompany Truvada use for PrEP are rarely serious and universally reverse after stopping the medication, but also that older people and those with the best adherence might need to b...
Research presented at CROI 2016 shows that Truvada PrEP is safe for most people, but impaired kidney function -- usually mild or moderate -- may occur in a small proportion of people on PrEP, especially if they have other risk factors.
Taking Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) has little effect on kidney function, according to a new study.